Improved Depth of Response and MRD Negativity with DARA + VRd in Transplant-Eligible NDMM: PERSEUS

Daratumumab (DARA) + bortezomib/lenalidomide/dexamethasone (VRd) in transplant-eligible (TE) patients (pts) with newly diagnosed multiple myeloma (NDMM): Analysis of minimal residual disease (MRD) in the PERSEUS trial
The PERSEUS trial analyzed the use of daratumumab (DARA) in combination with bortezomib/lenalidomide/dexamethasone (VRd) in transplant-eligible patients with newly diagnosed multiple myeloma (NDMM). The study aimed to evaluate the minimal residual disease (MRD) status and depth of response in patients receiving DARA-based therapy. The results showed that DARA + VRd induction/consolidation and DARA maintenance improved progression-free survival (PFS) and increased the depth of response compared to VRd induction/consolidation and lenalidomide (R) maintenance. The MRD-negative rates were higher with DARA + VRd, and the rates increased over time. Sustained MRD negativity for 12 months was also higher with DARA + VRd. The study concluded that DARA + VRd and DARA maintenance can be considered a new standard of care for transplant-eligible patients with NDMM.
Key Points:
1. The PERSEUS trial evaluated the use of daratumumab (DARA) in combination with bortezomib/lenalidomide/dexamethasone (VRd) in transplant-eligible patients with newly diagnosed multiple myeloma (NDMM).
2. DARA + VRd induction/consolidation and DARA maintenance improved progression-free survival (PFS) compared to VRd induction/consolidation and lenalidomide (R) maintenance.
3. The depth of response was higher with DARA + VRd, as evidenced by higher rates of complete response (CR) and MRD negativity.
4. MRD-negative rates increased over time and were consistently higher with DARA + VRd compared to VRd.
5. Sustained MRD negativity for 12 months was achieved by a greater proportion of patients receiving DARA + VRd.
6. The study concluded that DARA + VRd and DARA maintenance can be considered a new standard of care for transplant-eligible patients with NDMM.
Authors:
Paula Rodríguez-Otero, Philippe Moreau, Meletios Athanasios Dimopoulos, Meral Beksac, Aurore Perrot, Annemiek Broijl, Francesca Gay, Roberto Mina, Niels W.C.J. van de Donk, Fredrik Schjesvold, Michel Delforge, Hermann Einsele, Andrew Spencer, Sarah Lonergan, Diego Vieyra, Anna Sitthi-Amorn, Robin L. Carson, Joan Blade, Mario Boccadoro, and Pieter Sonneveld.
Clinical Trial Registration Number: NCT03710603
Abstract#7502
_______________
Improving Lives | Finding the Cure
Founded in 1990, the International Myeloma Foundation (IMF) is the first and largest organization focusing specifically on multiple myeloma. The IMF’s reach extends to more than 525,000 members in 140 countries worldwide. The IMF is dedicated to improving the quality of lives of myeloma patients while working toward prevention and a cure through our four founding principles: Research, Education, Support, and Advocacy.
Subscribe to our channel: / imfmyeloma
Visit our website at: www.myeloma.org
Find us online:
Facebook: @myeloma | / myeloma
Twitter: @IMFMyeloma | / imfmyeloma
Instagram: @imfmyeloma | / imfmyeloma
LinkedIn: / international-myeloma-...
Support the IMF | Donate Now! fundraise.myeloma.org/give/52...
Category
Nonprofits & Activism
License
Standard KZbin License
In most cases, captions are autogenerated by KZbin.